Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Skyworks (SWKS) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Skyworks between from August 8, 2023 to February 5, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareho ...

CALGARY, Alberta, July 22, 2025 (GLOBE NEWSWIRE) -- Pulse Seismic Inc. (TSX:PSD) (OTCQX:PLSDF) (“Pulse” or the “Company”) is pleased to report its financial and operating results for the three and six months ended June 30, 2025. The unaudited condensed consolidated interim financial statements, accompanying notes and MD&A are being filed on SEDAR+ (www.sedarplus.ca) and will be available on Pulse’s website at www.pulseseismic.com. Today, Pulse’s Board of Directors declared a regular quarterly dividend of $0 ...

Summary of the Conference Call Company and Industry Involved - **Companies**: MAS (MSP), High Prop (Hyprop), Prime Capital - **Industry**: Real Estate Investment Trusts (REITs), specifically focusing on retail and property development Core Points and Arguments 1. **Management Background**: The management team has extensive experience in real estate and investment banking, with previous roles in companies like RMB and Atterbury, indicating a strong foundation for handling complex transactions [6][12][40] 2. **Dividend Strategy**: High Prop has implemented a policy of paying only cash back dividends, moving away from accounting income that was not realized in cash, which has improved their capital structure [12][18] 3. **Debt Reduction**: High Prop has successfully reduced its consolidated loan-to-value (LTV) ratio from 52% during COVID to 36.3%, and European equity debt from €403 million to €75 million, indicating a strong focus on financial health [12][18] 4. **Acquisition Strategy**: High Prop is looking to acquire a significant stake in MAS as part of its diversification strategy, which aligns with its existing European portfolio [17][18] 5. **Earnings Impact**: Post-transaction, it is expected that approximately 60% of High Prop's earnings will be euro-based, significantly increasing the net asset value attributed to euro-denominated assets [18][41] 6. **Shareholder Engagement**: High Prop aims to improve shareholder engagement and reporting, with plans to resume dividend payments for MAS once liquidity issues are resolved [20][42] 7. **Complexity of DJV**: The joint venture (DJV) agreement with Prime Capital is seen as complex and potentially unfavorable for MAS shareholders, with concerns about governance and financial assistance [38][61] 8. **Voluntary Offer Details**: High Prop's voluntary offer includes a cash price of R24 per share, based on historical trading prices, and aims to provide liquidity for MAS shareholders [25][27] 9. **Risks of Non-Acceptance**: High Prop emphasizes the risks for MAS shareholders if they do not accept the offer, including potential declines in share value and unresolved issues within MAS [34][35] 10. **Management Team Proposal**: High Prop proposes to bring in experienced management from Rockcastle to lead MAS, emphasizing the importance of having a trustworthy management team [21][24] Other Important but Overlooked Content 1. **DJV Agreement Concerns**: There are significant concerns regarding the DJV agreement's structure and its implications for MAS's financial health, with calls for transparency and access to documentation [54][65] 2. **Market Conditions**: The current market conditions and the trading discounts of both MAS and High Prop shares are highlighted, indicating a need for strategic decision-making [25][34] 3. **Potential for Increased Cash Cap**: High Prop may consider increasing the cash cap from R800 million depending on the acceptance levels of the cash offer [27] 4. **Governance Issues**: There are worries about the governance at MAS, particularly regarding the board's consent for the DJV to buy shares, which raises questions about financial prudence [61][62] 5. **Future Strategy**: High Prop is prepared to explore other opportunities if the necessary support for the transaction is not achieved, indicating a strategic flexibility [28][29] This summary encapsulates the key discussions and insights from the conference call, providing a comprehensive overview of the strategic direction and challenges faced by High Prop and MAS.

ATLANTA, July 22, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed Alto Neuroscience, Inc. (“Alto” or the “Company”) (NYSE: ANRO). The lawsuit alleges that throughout the Class Period, and in the Company’s Offering Documents, Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information concerning Alto’s business, operations, and prospects, including allegations that: (i) ALTO-100 was less effective in treating MDD than Defenda ...

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for allegedly misleading investors regarding the viability of its drug candidates, particularly troriluzole and BHV-7000, during the period from March 24, 2023, to May 14, 2025 [1][2]. Group 1: Company Overview - Biohaven Ltd. is a biopharmaceutical company focused on developing therapies in immunology, neuroscience, and oncology [1]. - The company is working on several product candidates, including troriluzole for spinocerebellar ataxia (SCA) and BHV-7000 for bipolar disorder [1]. Group 2: Allegations and Legal Proceedings - The lawsuit alleges that Biohaven overstated the regulatory prospects and data sufficiency for troriluzole's approval for SCA [2]. - It is also claimed that the efficacy and clinical prospects of BHV-7000 for bipolar disorder were similarly overstated [2]. - The complaint suggests that the revelation of these issues could significantly negatively impact Biohaven's business and financial condition [2]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers by September 12, 2025 [3]. - Participation in the class action is not required to be eligible for recovery; shareholders can remain absent class members if they choose [3].

Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its drug candidate ALTO-100 during its IPO and subsequent period [1][2]. Group 1: Company Overview - Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company based in the U.S. with a product pipeline that includes ALTO-100, which was in a Phase 2b clinical trial for treating major depressive disorder (MDD) at the time of its IPO [1]. - The IPO occurred on or about February 2, 2024, and the class period for the lawsuit extends from this date to October 22, 2024 [1]. Group 2: Allegations and Misleading Information - The lawsuit alleges that the Offering Documents related to the IPO were negligently prepared and that the company failed to disclose critical information about ALTO-100's effectiveness [2]. - Specifically, it is claimed that ALTO-100 was less effective in treating MDD than represented, leading to overstated clinical, regulatory, and commercial prospects, which in turn inflated Alto's business and financial outlook [2]. Group 3: Impact of Clinical Trial Results - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in the Phase 2b trial, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) compared to placebo [3]. - Following this announcement, Alto's stock price plummeted by $10.17 per share, a decrease of 69.99%, closing at $4.36 per share on October 23, 2024 [3]. Group 4: Legal Proceedings - Shareholders interested in participating in the class action have until September 19, 2025, to seek lead plaintiff status, which allows them to represent other class members in the litigation [4]. - Participation in the case is not required to be eligible for recovery, and shareholders can choose to remain absent class members [4].

ATLANTA, July 21, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about UroGen’s business, operations, and prospects, including allegations that: (1) the ENVISION clinical study was not designed to demonstrate substantial evidence of effectiveness of UGN-102 because it la ...

ATLANTA, July 21, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Fortrea Holdings, Inc. (“Fortrea” or the “Company”) (NASDAQ: FTRE). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about Fortrea’s business, operations, and prospects, including allegations that: (i) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to the Company’s 2025 ea ...

MILWAUKEE, July 21, 2025 /PRNewswire/ -- The Ademi Firm is investigating PharmChem (OTC: PCHM) for possible breaches of fiduciary duty and other violations of law in its transaction with Alcohol Monitoring Systems.Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.In the transaction, shareholders of PharmChem will receive $3.75 per share in cash. PharmChem insiders will recei ...

Core Viewpoint - The Ademi Firm is investigating ZimVie for potential breaches of fiduciary duty and other legal violations related to its transaction with ARCHIMED, which involves a cash offer of $19.00 per share, totaling approximately $730 million in enterprise value [1][2]. Group 1 - ZimVie shareholders are set to receive $19.00 per share in cash, equating to an enterprise value of around $730 million [2]. - The transaction agreement includes provisions that significantly limit competing offers for ZimVie, imposing penalties if a competing bid is accepted [3]. - The investigation focuses on whether the ZimVie board of directors is adequately fulfilling their fiduciary responsibilities to all shareholders amidst these arrangements [3].